Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Amortization of Deferred Charges (2020)

Design Therapeutics' Amortization of Deferred Charges history spans 1 years, with the latest figure at $12000.0 for Q1 2020.

  • On a quarterly basis, Amortization of Deferred Charges changed N/A to $12000.0 in Q1 2020 year-over-year; TTM through Dec 2020 was $12000.0, a N/A change, with the full-year FY2020 number at $12000.0, changed N/A from a year prior.
  • Amortization of Deferred Charges hit $12000.0 in Q1 2020 for Design Therapeutics.
  • Over the last five years, Amortization of Deferred Charges for DSGN hit a ceiling of $12000.0 in Q1 2020 and a floor of $12000.0 in Q1 2020.